2.9 magnitude earthquake recorded in northern part of Denver metro area
The 2.9 magnitude quake was recorded in Dacono, about 30 miles north of Denver, around 6 a.m. and was felt by hundreds of people, according to the Geological Survey.
Despite being felt, it was considered a relatively weak earthquake. The Richter scale, which is the tool used to measure the strength of earthquakes, goes up to 10 and the U.S. Geological Survey says there are over 1 million earthquakes worldwide under a 3 on the scale each year.
A Dec. 22, 2018, Associated Press file photo shows a pump jack over an oil well along Interstate 25 near Dacono, Colorado.
David Zalubowski / AP
Most quakes under a 3 are hardly felt and property damage doesn't tend to occur under a 5 on the scale.
For context, most of the most destructive earthquakes in the last 100 years have been between a 6 and 8 magnitude. The 2004 Indian Ocean earthquake and tsunami that killed over 220,000 people was a 9.0 and the 2010 earthquake in Haiti that killed tens of thousands of people was a 7.0.
CBS Colorado First Alert Chief Meteorologist Dave Aguilera says earthquakes are rare in Colorado and those that can be felt are even rarer.
Dacono is in the southwestern portion of Weld County and the area is home to a number of oil wells, something nearby residents have voiced opposition to, and which some scientists say is to blame for an increased number and intensity of earthquakes. A 2014 study posted online in "Science" connected thousands of small earthquakes to oil and gas production.
A 6.6 magnitude earthquake in 1882 was the strongest recorded in Colorado since they started being recorded and tracked. Since then, at least six quakes of a 5.0 magnitude or higher have been recorded by the Colorado Geological Survey. Scientists have been warning about the possibility of a massive quake in the state.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
ImmunityBio, Inc. (IBRX) Gains UK Approval for ANKTIVA in Bladder Cancer
We recently compiled a list of ImmunityBio, Inc. stands eleventh on our list. ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best future stocks to buy now. It is transforming cancer care through immunotherapies that activate the body's natural defenses. Its lead therapy, ANKTIVA (nogapendekin alfa inbakicept), has already been approved by the FDA for treating certain types of bladder cancer. The company is now expanding its approach with a focus on reversing lymphopenia, an immune deficiency often caused by chemotherapy, radiation, or immunotherapy. In June 2025, the FDA authorized an Expanded Access Program for ANKTIVA under the Cancer BioShield platform, making it the first approved therapy to target treatment-induced lymphopenia in patients with solid tumors who failed standard therapies. At ASCO 2025, data showed that restoring immune health with ANKTIVA, especially when paired with CAR-NK therapy, can significantly improve survival in metastatic pancreatic cancer patients. Internationally, ImmunityBio, Inc. (NASDAQ:IBRX) is gaining momentum. In July 2025, the UK approved ANKTIVA with BCG for non-muscle invasive bladder cancer (NMIBC), marking its first approval outside the U.S. Additionally, a partnership with Saudi Arabia's health system will bring the Cancer BioShield platform to the Middle East. The company is also expanding clinical trials, including a U.S.-based study testing ANKTIVA with PD-1 inhibitors in non-small cell lung cancer (NSCLC), with plans to expand globally. Meanwhile, the business is seeking broader FDA approval for ANKTIVA + BCG in bladder cancer after addressing regulatory hurdles. A laboratory technician using high tech equipment to sequence cancer genomics. By targeting immune collapse caused by cancer treatments, ImmunityBio, Inc. (NASDAQ:IBRX) is introducing a paradigm shift, fighting both cancer and immune dysfunction simultaneously. With FDA designations, strategic global alliances, and promising clinical data, the company is advancing a potentially life-extending new standard in oncology. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 minutes ago
- Yahoo
Vaxcyte, Inc. (PCVX)'s VAX-24 Achieves Phase 2 Success in Infants
We recently compiled a list of Vaxcyte, Inc. stands second on our list among the best future stocks. Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage biotech company focused on developing next-generation pneumococcal conjugate vaccines (PCVs) to prevent invasive pneumococcal disease (IPD). The company recently reported positive topline results from its Phase 2 study of VAX-24 in infants. The 24-valent vaccine candidate met all primary endpoints for safety, tolerability, and immunogenicity compared to Pfizer's Prevnar 20, with robust immune responses and no serious vaccine-related adverse events. Full data following the fourth booster dose is expected by year-end 2025. Building on this progress, Vaxcyte, Inc. (NASDAQ:PCVX) is advancing VAX-31, a 31-valent PCV targeting broader strain coverage, approximately 94% in U.S. children and 95% in adults. The final stage of its infant Phase 2 trial is underway, with topline results expected by mid-2026. Adult Phase 3 trials are set to begin in mid-2025. VAX-31 has received FDA Breakthrough Therapy designation for adults and investigational approvals for pediatric use, highlighting its potential to address significant unmet medical needs. The business also unveiled VAX-XL, its third-generation PCV candidate offering the broadest coverage yet, signaling continued innovation in its pipeline. To support commercialization, Vaxcyte, Inc. (NASDAQ:PCVX) is constructing a manufacturing facility at Lonza, expected to be operational by early 2026. Its strong cash reserves of approximately $3 billion provide the necessary funding for R&D and scale-up. A biotechnologist in a laboratory wearing a lab coat, preparing samples for a clinical trial. Strategically, the corporation is aligning clinical, regulatory, and manufacturing efforts to become a leader in the global pneumococcal vaccine market. The recent appointment of Dr. Olivier Brandicourt, former CEO of Sanofi, to its board reinforces this vision with deep commercial expertise. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Times
7 minutes ago
- New York Times
Energy Dept. Attacks Climate Science in Contentious Report
Sea level rise is not accelerating. More carbon dioxide in the atmosphere will be good for plant growth. The computer models used to predict global warming tend to exaggerate future temperature increases. These arguments, routinely made by people who reject the scientific consensus on climate change, were included in an unusual report released by the Energy Department on Tuesday. The report, which is meant to support the Trump administration's sweeping efforts to roll back climate regulations, contends that the mainstream scientific view on climate change is too dire and overlooks the positive effects of a warming planet. Climate scientists said the 151-page report misrepresented or cherry-picked a large body of research on global warming. Zeke Hausfather, a climate scientist at Berkeley Earth and the payments company Stripe, called the document a 'scattershot collection of oft-debunked skeptic claims' that 'are not representative of broader climate science research findings.' The report demonstrates the extent to which President Trump is using his second term to wage a battle against climate change research, a long-held goal of some conservative groups and fossil fuel companies. While the first Trump administration often undermined federal scientists and rolled back more than 100 environmental policies, officials mostly refrained from trying to debate climate science in the open. This time, Trump officials have gone much further. The Environmental Protection Agency this week cited the Energy Department report in its proposal to repeal a landmark 2009 finding that greenhouse gases, including carbon dioxide, pose a threat to public health. That determination, known as the endangerment finding, underpinned the agency's legal authority to limit greenhouse gas emissions from cars, power plants and other industrial sources of pollution. Want all of The Times? Subscribe.
